A Task Force was established by the International Restless Legs Syndrome Study Group (IRLSSG) to develop evidence-based and consensus-based recommendations for the long-term pharmacologic treatment of restless legs syndrome/Willis-Ekbom disease (RLS/WED). The Task Force reviewed the results of all studies of RLS/WED treatments with durations of 6 months or longer presented at meetings over the past 2 years, posted on Web sites of pharmaceutical companies, or published in peer-reviewed journals, asking the questions, "What is the efficacy of this treatment in patients with RLS/WED?" and "What is the safety of this treatment in patients with RLS/WED?" The Task Force developed guidelines based on their review of 61 papers meeting inclusion criteria, and using a modified evidence-grading scheme. Pregabalin has been established as effective for up to 1 year in treating RLS/WED (Level A evidence). Pramipexole, ropinirole, and rotigotine have been established as effective for up to 6 months in treating RLS/WED (Level A). The following drugs have been established as probably effective (Level B) in treating RLS/WED for durations ranging from 1 to 5 years: gabapentin enacarbil, pramipexole, and ropinirole (1 year); levodopa (2 years); and rotigotine (5 years). Because of associated safety concerns, pergolide and cabergoline should not be used in the treatment of RLS/WED unless the benefits clearly outweigh the risks. Other pharmacologic therapies have insufficient evidence to support their long-term use in treating RLS/WED. The IRLSSG Task Force also developed consensus-based strategies for the prevention and treatment of complications (such as augmentation, loss of efficacy, excessive daytime sleepiness, and impulse control disorders) that may develop with the long-term pharmacologic treatment of RLS/WED. The use of either a dopamine-receptor agonist or α2δ calcium-channel ligand is recommended as the first-line treatment of RLS/WED for most patients, with the choice of agent dependent on the patient's severity of RLS/WED symptoms, cognitive status, history, and comorbid conditions.
A Task Force was established by the International Restless Legs Syndrome Study Group ( IRLSSG ) to develop evidence - based and consensus - based recommendations for the long - term pharmacologic treatment of restless legs syndrome / Willis - Ekbom disease ( RLS / WED ) . The Task Force reviewed the results of all studies of RLS / WED treatments with durations of 6 months or longer presented at meetings over the past 2 years , posted on Web sites of pharmaceutical companies , or published in peer - reviewed journals , asking the questions , " What is the efficacy of this treatment in patients with RLS / WED ? " and " What is the safety of this treatment in patients with RLS / WED ? " The Task Force developed guidelines based on their review of 61 papers meeting inclusion criteria , and using a modified evidence - grading scheme . Pregabalin has been established as effective for up to 1 year in treating RLS / WED ( Level A evidence ) . Pramipexole , ropinirole , and rotigotine have been established as effective for up to 6 months in treating RLS / WED ( Level A ) . The following drugs have been established as probably effective ( Level B ) in treating RLS / WED for durations ranging from 1 to 5 years : gabapentin enacarbil , pramipexole , and ropinirole ( 1 year ) ; levodopa ( 2 years ) ; and rotigotine ( 5 years ) . Because of associated safety concerns , pergolide and cabergoline should not be used in the treatment of RLS / WED unless the benefits clearly outweigh the risks . Other pharmacologic therapies have insufficient evidence to support their long - term use in treating RLS / WED . The IRLSSG Task Force also developed consensus - based strategies for the prevention and treatment of complications ( such as augmentation , loss of efficacy , excessive daytime sleepiness , and impulse control disorders ) that may develop with the long - term pharmacologic treatment of RLS / WED . The use of either a dopamine - receptor agonist or α2δ calcium - channel ligand is recommended as the first - line treatment of RLS / WED for most patients , with the choice of agent dependent on the patient 's severity of RLS / WED symptoms , cognitive status , history , and comorbid conditions .
Willis-Ekbom disease is also known as?
Willis - Ekbom disease is also known as ?
Restless legs syndrome
Restless legs syndrome